Gaur et al.

Dzau VJ, Sasamura H, Hein L. 1993. Heterogeneity of angiotensin synthetic pathways

and receptor subtypes: physiological and pharmacological implications. J Hypertens .

11 (suppl 3): S13–S22.

Linz W, Wiemer G, Gohlke P, et al. 1995. Contribution of kinins to the cardiovascular

actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47 :25–49.

Olin BR. 2002. Drug Facts and Comparisons. St. Louis: JB Lippincott Co. pp. 514–518.

Rodgers JE, Patterson JH. 2001. Angiotensin II-receptor blockers: clinical relevance and

therapeutic role. Am J Health Syst Pharm. 58 : 671–683.

Sankyo Pharma Inc (US) Benicar(®) (Olmesartan Medoxomil) [product monograph] New

York: Advantage Communications; 2002. Expanding the Paradigm for Hypertension

Management with a New Angiotensin II Receptor Blacker.

Urata K, Kinoshita A, Misono K, et al. 1990. Identification of a highly specific chymase as

the major angiotensin-forming enzyme in the human heart. J Biol Chem. 265 : 22348–

22382.

152

International Journal of Bioinformatics and Biological Sciences : v.2 n.3&4. Dec. 2014